Zoetis Inc
ZTS127.890USD
+5.020+4.09%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
56.46BMarket Cap
21.30P/E TTM
More Details of Zoetis Inc Company
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. It is engaged in commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Zoetis Inc Info
Ticker SymbolZTS
Company nameZoetis Inc
IPO dateFeb 01, 2013
CEOMs. Kristin C. Peck
Number of employees13800
Security typeOrdinary Share
Fiscal year-endFeb 01
Address10 Sylvan Way
CityPARSIPPANY
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code07054
Phone19738227000
Websitehttps://www.zoetis.com/
Ticker SymbolZTS
IPO dateFeb 01, 2013
CEOMs. Kristin C. Peck
Company Executives of Zoetis Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+0.02%
Mr. Michael B. Mccallister
Mr. Michael B. Mccallister
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.86K
-6.61%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+12.20%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Frank A. D'amelio
Mr. Frank A. D'amelio
Independent Director
Independent Director
14.81K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Dr. Robert J. (Rob) Polzer, Ph.D.
Dr. Robert J. (Rob) Polzer, Ph.D.
Executive Vice President, President - Research and Development
Executive Vice President, President - Research and Development
6.19K
+0.39%
Ms. Rimma Driscoll
Ms. Rimma Driscoll
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
Executive Vice President and Head of Global Strategy, Commercial and Business Development, and Global BioDevices
5.19K
+8.28%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Independent Director
Independent Director
2.82K
+51.75%
Mr. Jamie Brannan
Mr. Jamie Brannan
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
2.59K
+19.25%
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Kristin C. Peck
Ms. Kristin C. Peck
Chief Executive Officer, Director
Chief Executive Officer, Director
95.01K
+0.02%
Mr. Michael B. Mccallister
Mr. Michael B. Mccallister
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
25.86K
-6.61%
Mr. Gregory (Greg) Norden
Mr. Gregory (Greg) Norden
Independent Director
Independent Director
16.95K
+12.20%
Ms. Louise M. Parent
Ms. Louise M. Parent
Independent Director
Independent Director
15.26K
--
Mr. Frank A. D'amelio
Mr. Frank A. D'amelio
Independent Director
Independent Director
14.81K
--
Mr. Sanjay Khosla
Mr. Sanjay Khosla
Independent Director
Independent Director
9.81K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Parasiticides
673.00M
27.36%
Vaccines
504.00M
20.49%
Dermatology
463.00M
18.82%
Anti-infectives
219.00M
8.90%
Pain and sedation
217.00M
8.82%
Other
384.00M
15.61%
By RegionUSD
Name
Revenue
Proportion
United States
1.36B
55.12%
Other emerging markets
225.00M
9.15%
Other Developed
162.00M
6.59%
Brazil
93.00M
3.78%
Australia
83.00M
3.37%
Other
541.00M
21.99%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Parasiticides
673.00M
27.36%
Vaccines
504.00M
20.49%
Dermatology
463.00M
18.82%
Anti-infectives
219.00M
8.90%
Pain and sedation
217.00M
8.82%
Other
384.00M
15.61%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.55%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Other
74.46%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.55%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.46%
State Farm Insurance Companies
3.83%
Geode Capital Management, L.L.C.
2.53%
Other
74.46%
Shareholder Types
Shareholders
Proportion
Investment Advisor
49.05%
Investment Advisor/Hedge Fund
32.09%
Research Firm
4.42%
Insurance Company
3.92%
Bank and Trust
2.62%
Pension Fund
2.55%
Hedge Fund
1.56%
Sovereign Wealth Fund
1.25%
Family Office
0.15%
Other
2.40%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
3275
435.62M
98.29%
-1.39M
2025Q2
3277
434.35M
98.00%
-1.58M
2025Q1
3284
432.42M
97.12%
-4.21M
2024Q4
3199
430.60M
96.14%
-9.58M
2024Q3
3090
434.14M
95.81%
-13.19M
2024Q2
3062
437.75M
95.94%
-9.33M
2024Q1
3060
439.45M
96.16%
-2.63M
2023Q4
3074
438.13M
95.43%
-2.08M
2023Q3
2966
434.04M
94.28%
-3.00M
2023Q2
2949
430.67M
93.19%
-11.77M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
41.69M
9.41%
+326.69K
+0.79%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
22.66M
5.11%
-498.13K
-2.15%
Jun 30, 2025
State Street Investment Management (US)
19.74M
4.45%
-59.31K
-0.30%
Jun 30, 2025
State Farm Insurance Companies
16.84M
3.8%
-34.10K
-0.20%
Jun 30, 2025
Geode Capital Management, L.L.C.
11.08M
2.5%
+95.29K
+0.87%
Jun 30, 2025
Wellington Management Company, LLP
8.89M
2.01%
+2.82M
+46.56%
Jun 30, 2025
Polen Capital Management, LLC
8.42M
1.9%
-375.82K
-4.27%
Jun 30, 2025
Morgan Stanley Investment Management Ltd. (UK)
6.75M
1.52%
+4.58M
+209.96%
Jun 30, 2025
Wells Fargo Advisors
5.83M
1.32%
-180.38K
-3.00%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
5.19M
1.17%
+131.36K
+2.60%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ProShares Pet Care ETF
9.91%
VanEck Agribusiness ETF
7.63%
VanEck Pharmaceutical ETF
4.34%
iShares U.S. Pharmaceuticals ETF
4.32%
Honeytree US Equity ETF
3.92%
First Trust NASDAQ Pharmaceuticals ETF
3.43%
Polen Capital Global Growth ETF
3.35%
iShares ESG Aware MSCI USA Value ETF
3.19%
SPDR S&P Pharmaceuticals ETF
2.35%
Siren DIVCON Dividend Defender ETF
2.07%
View more
ProShares Pet Care ETF
Proportion9.91%
VanEck Agribusiness ETF
Proportion7.63%
VanEck Pharmaceutical ETF
Proportion4.34%
iShares U.S. Pharmaceuticals ETF
Proportion4.32%
Honeytree US Equity ETF
Proportion3.92%
First Trust NASDAQ Pharmaceuticals ETF
Proportion3.43%
Polen Capital Global Growth ETF
Proportion3.35%
iShares ESG Aware MSCI USA Value ETF
Proportion3.19%
SPDR S&P Pharmaceuticals ETF
Proportion2.35%
Siren DIVCON Dividend Defender ETF
Proportion2.07%
Dividend
A total of
2.94B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 12, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.5 paid on Mar 04, 2025 going ex on Jan 21, 2025
Jan 21, 2025
Mar 04, 2025
Jan 21, 2025
Oct 10, 2024
ZTS.NB Final Cash Dividend of gross USD 0.432 paid on Dec 03, 2024 going ex on Oct 31, 2024
Oct 31, 2024
Dec 03, 2024
Oct 31, 2024
May 22, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Sep 04, 2024 going ex on Jul 18, 2024
Jul 18, 2024
Sep 04, 2024
Jul 18, 2024
Feb 06, 2024
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Jun 04, 2024 going ex on Apr 18, 2024
Apr 19, 2024
Jun 04, 2024
Apr 18, 2024
Dec 07, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.432 paid on Mar 01, 2024 going ex on Jan 18, 2024
Jan 19, 2024
Mar 01, 2024
Jan 18, 2024
Oct 12, 2023
ZTS.NB Final Cash Dividend of gross USD 0.375 paid on Dec 01, 2023 going ex on Oct 31, 2023
Nov 01, 2023
Dec 01, 2023
Oct 31, 2023
May 11, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Sep 01, 2023 going ex on Jul 20, 2023
Jul 21, 2023
Sep 01, 2023
Jul 20, 2023
Feb 08, 2023
ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Jun 01, 2023 going ex on Apr 20, 2023
Apr 21, 2023
Jun 01, 2023
Apr 20, 2023
Dec 08, 2022
ZTS.NB Interim Cash Dividend of gross USD 0.375 paid on Mar 01, 2023 going ex on Jan 19, 2023
Jan 20, 2023
Mar 01, 2023
Jan 19, 2023
Oct 13, 2022
ZTS.NB Final Cash Dividend of gross USD 0.325 paid on Dec 01, 2022 going ex on Oct 31, 2022
Nov 01, 2022
Dec 01, 2022
Oct 31, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Zoetis Inc?
The top five shareholders of Zoetis Inc are:
The Vanguard Group, Inc. holds 41.69M shares, accounting for 9.41% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 22.66M shares, accounting for 5.11% of the total shares.
State Street Investment Management (US) holds 19.74M shares, accounting for 4.45% of the total shares.
State Farm Insurance Companies holds 16.84M shares, accounting for 3.80% of the total shares.
Geode Capital Management, L.L.C. holds 11.08M shares, accounting for 2.50% of the total shares.
The Vanguard Group, Inc. holds 41.69M shares, accounting for 9.41% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 22.66M shares, accounting for 5.11% of the total shares.
State Street Investment Management (US) holds 19.74M shares, accounting for 4.45% of the total shares.
State Farm Insurance Companies holds 16.84M shares, accounting for 3.80% of the total shares.
Geode Capital Management, L.L.C. holds 11.08M shares, accounting for 2.50% of the total shares.
What are the top three shareholder types of Zoetis Inc?
The top three shareholder types of Zoetis Inc are:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
How many institutions hold shares of Zoetis Inc (ZTS)?
As of 2025Q3, 3275 institutions hold shares of Zoetis Inc, with a combined market value of approximately 435.62M, accounting for 98.29% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.29%.
What is the biggest source of revenue for Zoetis Inc?
In FY2025Q2, the Parasiticides business generated the highest revenue for Zoetis Inc, amounting to 673.00M and accounting for 27.36% of total revenue.
